Tecentriq Hybreza Interactions
There are 701 drugs known to interact with Tecentriq Hybreza (atezolizumab/hyaluronidase), along with 13 disease interactions. Of the total drug interactions, 25 are major, 609 are moderate, and 67 are minor.
- View all 701 medications that may interact with Tecentriq Hybreza
- View Tecentriq Hybreza disease interactions (13)
Most frequently checked interactions
View interaction reports for Tecentriq Hybreza (atezolizumab / hyaluronidase) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Addyi (flibanserin)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Alhemo (concizumab)
- Altuviiio (antihemophilic factor)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- Andembry (garadacimab)
- apremilast
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blenrep (belantamab mafodotin)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
- Briumvi (ublituximab)
Tecentriq Hybreza disease interactions
There are 13 disease interactions with Tecentriq Hybreza (atezolizumab / hyaluronidase) which include:
- endocrinopathies
- hepatitis
- infections
- meningitis
- neuropathy
- pancreatitis
- colitis
- liver disease
- pneumonitis
- renal impairment
- HSCT
- myasthenia gravis
- organ transplant
More about Tecentriq Hybreza (atezolizumab / hyaluronidase)
- Tecentriq Hybreza consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.